Search Medical Condition
Please enter condition
Please choose location from dropdown

Daejon, Korea, Republic of Clinical Trials

A listing of Daejon, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (116) clinical trials

Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)

1. EULAR Response after 24weeks of treatment 2. EULAR Response after 12weeks of treatment 3. DAS28 value change 4. KHAQ-20 value change

Phase

0.0 miles

Learn More »

Drug-Eluting Balloon Registry in Routine Clinical Practice

The purpose of this study is to evaluate long-term effectiveness and safety of patients with coronary disease treated with drug eluting balloon in real world practice.

Phase N/A

0.0 miles

Learn More »

XIENCE Xpedition/Alpine in Routine Clinical Practice

The purpose of this study is to evaluate effectiveness and safety of XIENCE xpedition/Alpine in Routine Clinical Practice

Phase N/A

0.0 miles

Learn More »

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in the ...

Phase

0.0 miles

Learn More »

A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Na ve to Tumor Necrosis Factor (TNF) Inhibitors

This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to severe ulcerative colitis (UC) who are naive to tumor necrosis factor (TNF) inhibitors. Participants will be randomized in a 1:1 ratio ...

Phase

0.0 miles

Learn More »

Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide. In the past few decades, optimal pharmacological therapies with statins targeting LDL-cholesterol substantially reduce the risks of cardiovascular disease. However, the residual cardiovascular risk is still high, requiring need for additional preventive therapies to achieve even greater risk reduction. ...

Phase

0.0 miles

Learn More »

Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ

The objective of this study is to determine any problems or questions associated with Pristiq after marketing, with regard to the following clauses under conditions of general clinical practice, in compliance with the regulation "Re-examination guideline of new drugs (Ministry of Food and Drug Safety Notification 2013-251, 2013.12.20)". Serious adverse ...

Phase N/A

0.0 miles

Learn More »

Mucopolysaccharidosis I (MPS I) Registry

The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com In Europe - +31-35-699-1232, europe@mpsiregistry.com In Latin America - +617-591-5500, help@mpsiregistry.com In North America - +617-591-5500, help@mpsiregistry.com

Phase N/A

0.0 miles

Learn More »

IRIS-Onyx Cohort in the IRIS-DES Registry

The purpose of this study is to evaluate the relative effectiveness and safety of Onyx stent compared to other (drug eluting stents) DES.

Phase N/A

0.0 miles

Learn More »

Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)

Prospective, two arms, randomized multi-center trial in Asian-pacific region. Following angiography, patients with chronic total occlusion (more than 3 months) have documented myocardial ischemia or symptoms of angina, and eligible for stenting without any exclusion criteria will be randomized 1:1 to: a) drug-eluting stent vs. b) optimal medical treatment. All ...

Phase

0.0 miles

Learn More »